Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPT Regimen for NK/T Cell Lymphoma
NCT04899414Phase 2Unknown
- Sponsor
- Peking University
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Peking University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04899414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899414.